Literature DB >> 21665507

Adult renal cell carcinoma with rhabdoid morphology represents a neoplastic dedifferentiation analogous to sarcomatoid carcinoma.

Jennifer R Chapman-Fredricks1, Loren Herrera, Jorge Bracho, Carmen Gomez-Fernandez, Raymond Leveillee, Luis Rey, Merce Jorda.   

Abstract

Renal cell carcinoma (RCC) with rhabdoid morphology (RCC-RM) is a recently described variant of RCC, which has an aggressive biologic behavior and poor prognosis, akin to sarcomatoid RCC. The current World Health Organization classification of RCC does not include the rhabdoid phenotype as a distinct histologic entity. The aim of this study is to investigate whether RCC-RM represents a dedifferentiation of a classifiable-type World Health Organization RCC or a carcinosarcoma with muscle differentiation. We reviewed 168 cases of RCC obtained between 2003 and 2008. From these cases, 10 (6%) were found to have areas of classic rhabdoid morphology. Immunohistochemistry for cytokeratin, epithelial membrane antigen, desmin, CD10, and CD117 was performed in each case using the labeled streptavidin-biotin method. Rhabdoid differentiation was identified in association with conventional-type RCC (9) and with unclassifiable-type RCC with spindle cell morphology (1). In all cases, both the rhabdoid and nonrhabdoid tumoral areas were positive for cytokeratin and epithelial membrane antigen and negative for desmin. Cytokeratin positivity in the rhabdoid areas was focal. In cases associated with conventional-type RCC, CD10 was positive in both the rhabdoid and nonrhabdoid foci. CD117 was negative in these tumors. The unclassifiable-type RCC with spindle cell morphology was negative for both CD10 and CD117. The similar immunophenotype between the rhabdoid and nonrhabdoid tumoral foci supports the origin of the rhabdoid cells from the classifiable-type RCC. Areas of rhabdoid morphology do not represent muscle metaplastic differentiation. Renal cell carcinoma with rhabdoid morphology may represent a dedifferentiation of a classifiable-type RCC, similar to that of sarcomatoid differentiation. The recognition of RCC-RM is important as it allows for the inclusion of these high-grade malignancies into a category associated with poor prognosis despite lacking the spindle cell component classically identified as sarcomatoid change.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21665507     DOI: 10.1016/j.anndiagpath.2011.03.002

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  13 in total

1.  Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous.

Authors:  Laura Zaldumbide; Asier Erramuzpe; Rosa Guarch; Jesús M Cortés; José I López
Journal:  Virchows Arch       Date:  2014-11-05       Impact factor: 4.064

Review 2.  Diagnostic approach to eosinophilic renal neoplasms.

Authors:  Oleksandr N Kryvenko; Merce Jorda; Pedram Argani; Jonathan I Epstein
Journal:  Arch Pathol Lab Med       Date:  2014-11       Impact factor: 5.534

3.  Renal cell carcinoma with rhabdoid and sarcomatoid features presented as a metastatic thigh mass with an unusual immunohistochemical profile.

Authors:  Asmaa Gaber Abdou; Mona Kandil; Soliman Elshakhs; Marwa Serag El-Dien; Rania Abdallah
Journal:  Rare Tumors       Date:  2014-03-18

4.  Coexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): implications for a possible role of SWI/SNF complex in the pathogenesis of RCC.

Authors:  Qiu Rao; Qiu-Yuan Xia; Qin Shen; Shan-Shan Shi; Pin Tu; Qun-Li Shi; Xiao-Jun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

5.  Extensive peritoneal carcinomatosis secondary to renal cell carcinoma with sarcomatoid and rhabdoid differentiation.

Authors:  Ashwini K Esnakula; Tammey J Naab; William Green; Babak Shokrani
Journal:  BMJ Case Rep       Date:  2013-04-22

6.  Renal cell carcinoma with rhabdoid-like features lack intracytoplasmic inclusion bodies and show aggressive behavior.

Authors:  Masaaki Sugimoto; Kenichi Kohashi; Kentaro Kuroiwa; Tatsuro Abe; Yuichi Yamada; Masaki Shiota; Kenjiro Imada; Seiji Naito; Yoshinao Oda
Journal:  Virchows Arch       Date:  2015-12-09       Impact factor: 4.064

7.  Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma.

Authors:  Onder Kara; Matthew J Maurice; Homayoun Zargar; Ercan Malkoc; Oktay Akca; Hiury S Andrade; Daniel Ramirez; Peter A Caputo; Ryan J Nelson; Brian Rini; Jihad H Kaouk
Journal:  Int Urol Nephrol       Date:  2016-05-23       Impact factor: 2.370

8.  Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.

Authors:  Rajesh R Singh; Paari Murugan; Lalit R Patel; Horatiu Voicu; Suk-Young Yoo; Tadeusz Majewski; Meenakshi Mehrotra; Khalida Wani; Nizar Tannir; Jose A Karam; Eric Jonasch; Christopher G Wood; Chad J Creighton; L Jeffrey Medeiros; Russell R Broaddus; Pheroze Tamboli; Keith A Baggerly; Kenneth D Aldape; Bogdan Czerniak; Rajyalakshmi Luthra; Kanishka Sircar
Journal:  Mod Pathol       Date:  2015-06-26       Impact factor: 7.842

9.  BAP1 loss defines a new class of renal cell carcinoma.

Authors:  Samuel Peña-Llopis; Silvia Vega-Rubín-de-Celis; Arnold Liao; Nan Leng; Andrea Pavía-Jiménez; Shanshan Wang; Toshinari Yamasaki; Leah Zhrebker; Sharanya Sivanand; Patrick Spence; Lisa Kinch; Tina Hambuch; Suneer Jain; Yair Lotan; Vitaly Margulis; Arthur I Sagalowsky; Pia Banerji Summerour; Wareef Kabbani; S W Wendy Wong; Nick Grishin; Marc Laurent; Xian-Jin Xie; Christian D Haudenschild; Mark T Ross; David R Bentley; Payal Kapur; James Brugarolas
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

10.  Hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a rapid autopsy report of metastatic renal cell carcinoma.

Authors:  Aaron M Udager; Ajjai Alva; Ying-Bei Chen; Javed Siddiqui; Amir Lagstein; Satish K Tickoo; Victor E Reuter; Arul M Chinnaiyian; Rohit Mehra
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.